AstraZeneca plc (LON:AZN) has been given a GBX 4,700 ($62.45) price objective by stock analysts at Morgan Stanley in a note issued to investors on Friday. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target would suggest a potential downside of 9.18% from the stock’s previous close.

AZN has been the topic of a number of other reports. Liberum Capital reiterated a “buy” rating and set a GBX 4,800 ($63.78) price target on shares of AstraZeneca plc in a research report on Tuesday, September 5th. HSBC Holdings plc increased their price target on shares of AstraZeneca plc from GBX 4,100 ($54.48) to GBX 4,150 ($55.14) and gave the company a “reduce” rating in a research report on Monday, October 9th. UBS AG set a GBX 4,550 ($60.46) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a research report on Thursday, August 31st. Jefferies Group LLC increased their price target on shares of AstraZeneca plc from GBX 4,350 ($57.80) to GBX 4,800 ($63.78) and gave the company a “hold” rating in a research report on Monday, September 11th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,700 ($75.74) price target on shares of AstraZeneca plc in a research report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of “Hold” and an average price target of GBX 5,172.64 ($68.73).

AstraZeneca plc (AZN) traded down 0.21% during midday trading on Friday, reaching GBX 5164.00. 1,070,114 shares of the company’s stock were exchanged. The firm has a 50 day moving average of GBX 4,904.35 and a 200-day moving average of GBX 4,912.64. The stock’s market cap is GBX 65.38 billion. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/20/astrazeneca-plc-azn-given-a-gbx-4700-price-target-at-morgan-stanley.html.

In other news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.